SPECT/CT Lymphoscintigraphy Accurately Localizes Clipped and Sentinel Nodes After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer.
Humans
Female
Breast Neoplasms
/ diagnostic imaging
Sentinel Lymph Node
/ diagnostic imaging
Neoadjuvant Therapy
Lymphoscintigraphy
Lymphatic Metastasis
/ pathology
Sentinel Lymph Node Biopsy
/ methods
Lymph Nodes
/ pathology
Lymph Node Excision
/ methods
Single Photon Emission Computed Tomography Computed Tomography
Lymphadenopathy
Surgical Instruments
Axilla
/ pathology
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 Jul 2023
01 Jul 2023
Historique:
medline:
7
6
2023
pubmed:
19
4
2023
entrez:
19
04
2023
Statut:
ppublish
Résumé
The aim of this study was to evaluate the impact of SPECT/CT lymphoscintigraphy on targeted axillary dissection (TAD) in node-positive breast cancer (BC) patients who had undergone neoadjuvant chemotherapy (NAC). Sixty-two female BC patients with biopsy-confirmed axillary nodal metastases underwent NAC, followed by breast surgery with TAD. A metallic clip was placed in the sampled LN before NAC. On the day of surgery, a periareolar intradermal 99m Tc-nanocolloid injection was administered, followed by SPECT/CT lymphoscintigraphy. The clipped nodes were localized on CT images, assessed for 99m Tc uptake before surgery, and confirmed during the procedure. T1-4, N1-2 patients were enrolled in the study. All patients underwent sentinel lymph node (SLN) biopsy. The clipped node was the SLN in 54 (88.5%) patients. In 3 patients (4.9%), a clip was found in a nonsentinel lymph node. In 4 patients, the clips were not visible on SPECT/CT images, and lymph nodes were not found during the procedure. SPECT/CT correctly localized the clipped lymph node in all patients. The overall false-negative rate for TAD was 3.33%. The mean follow-up duration was 29 months, and there were no axillary recurrences. SPECT/CT lymphoscintigraphy can accurately localize clipped nodes and SLNs after NAC in patients with node-positive BC.
Identifiants
pubmed: 37075247
doi: 10.1097/RLU.0000000000004669
pii: 00003072-202307000-00006
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
594-599Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared.
Références
Pilewskie M, Morrow M. Axillary nodal management following neoadjuvant chemotherapy, a review. JAMA Oncol . 2017;3:549–555.
Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol . 2007;25:3657–3663.
Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy inpatient with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol . 2013;14:609–618.
Boughey JC, Suman VJ, Mittendorf EA, et al; Alliance for Clinical Trials in Oncology. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA . 2013;310:1455–1461.
Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol . 2016;34:1072–1078.
Boughey JC, Ballman KV, Le-Petross HT, et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0-T4, N1-N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (Alliance). Ann Surg . 2016;263:802–807.
Donker M, Straver ME, Wesseling J, et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients. Ann Surg . 2015;261:378–382.
Caudle AS, Yang WT, Mittendorf EA, et al. Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial. JAMA Surg . 2015;150:137–143.
Has Simsek D, Emiroglu S, Yilmaz R, et al. SPECT/CT lymphoscintigraphy guidance simplifies and improves targeted axillary dissection of the clipped nodes after neoadjuvant chemotherapy in initially node-positive breast cancer. Clin Nucl Med . 2022;47:e682–e688.
Straver ME, Loo CE, Alderliesten T, et al. Marking the axilla with radioactive iodine seeds (MARI procedure) may reduce the need for axillary dissection after neoadjuvant chemotherapy for breast cancer. Br J Surg . 2010;97:1226–1231.
Choy N, Lipson J, Porter C, et al. Initial results with preoperative tattooing of biopsied axillary lymph nodes and correlation to sentinel lymph nodes in breast cancer patients. Ann Surg Oncol . 2015;22:377–382.
Baker JL, Haji F, Kusske AM, et al. SAVI SCOUT® localization of metastatic axillary lymph node prior to neoadjuvant chemotherapy for targeted axillary dissection: a pilot study. Breast Cancer Res Treat . 2022;191:107–114.
Nguyen TT, Hieken TJ, Glazebrook KN, et al. Localizing the clipped node in patients with node-positive breast cancer treated with neoadjuvant chemotherapy: early learning experience and challenges. Ann Surg Oncol . 2017;24:3011–3016.
Kuemmel S, Heil J, Rueland A, et al. A prospective, multicenter registry study to evaluate the clinical feasibility of targeted axillary dissection (TAD) in node-positive breast cancer patients. Ann Surg . 2022;276:e553–e562.
Trinh L, Miyake K, Dirbas F, et al. CT-guided wire localization for involved axillary lymph nodes after neoadjuvant chemotherapy in patients with initially node-positive breast cancer. Breast J . 2016;22:390–396.
Berberoglu K, Erdemir A, Rasa K, et al. Role of gamma probe-assisted intraoperative sentinel lymph node evaluation in predicting axillary breast cancer metastasis after neoadjuvant chemotherapy. Nucl Med Commun . 2020;41:120–125.
Ghosh D, Michalopoulos NV, Davidson T, et al. Sentinel node detection in early breast cancer with intraoperative portable gamma camera: UK experience. Breast . 2017;32:53–59.
Lerman H, Lievshitz G, Zak O, et al. Improved sentinel node identification by SPECT/CT in overweight patients with breast cancer. J Nucl Med . 2007;48:201–206.
Barrio AV, Montagna G, Mamtani A, et al. Nodal recurrence in patients with node-positive breast cancer treated with sentinel node biopsy alone after neoadjuvant chemotherapy—a rare event. JAMA Oncol . 2021;7:1851–1855.
Dilege E, Falay O, Agcaoglu O, et al. Role of SPECT/CT in detection of the marked metastatic lymph node and the sentinel node, after neoadjuvant chemotherapy in patients with breast cancer. Breast . 2021;56(suppl 1):S78.
Gallagher KK, Iles K, Kuzmiak C, et al. Prospective evaluation of radar-localized reflector-directed targeted axillary dissection in node-positive breast cancer patients after neoadjuvant systemic therapy. J Am Coll Surg . 2022;234:538–545.